China Tranexamic Acid Market Size & Outlook, 2026-2034
China Tranexamic Acid Market Insights
- As highlighted in Reed Intelligence analysis, the China Tranexamic Acid Market, worth USD 76.51 Million in 2025, is forecasted to achieve USD 141.42 Million by 2034.
- The China market is anticipated to grow at a CAGR of 7.11% during the period 2026–2034.
- By 2025, Injectable represented the largest share of the Type market size.
- Topical is expected to remain the key growth driver within Type, registering the fastest CAGR during the forecast period.
![China Tranexamic Acid Market Size, Share & Growth Report By [2034]](https://reedintelligence.com/uploads/charts/china-tranexamic-acid-market-china-type-90660.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, China accounted for 7.29% of the global Tranexamic Acid Market size.
- By 2034, United States is expected to lead the global Tranexamic Acid Market in terms of market size.
- Within Asia Pacific, China is projected to dominate the regional Tranexamic Acid Market size by 2034.
- Taiwan is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 18.96 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 76.51 Million |
| Market Size In 2034 | USD 141.42 Million |
| Largest segment | Injectable |
| Units | Revenue in USD Million |
| CAGR | 7.11% (2026-2034) |
| Segmnetation Covered | |
| Type |
|
| Application |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
China Tranexamic Acid Market Type 2026-2034 (USD Million)
| Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injectable | XX.x | XX.x | XX.x | 35.1 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Oral | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Topical | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
China Tranexamic Acid Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical | XX.x | XX.x | XX.x | 37.43 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Trauma | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gynecology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Dermatology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
China Tranexamic Acid Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 38.03 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.